Sun paper: the subsidiary plans to acquire 100% equity of Liujing Chengquan with 1.5 billion yuan

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

15 Chinese Companies to Watch in January 2023 - Mobility

We at EqualOcean tracked the major funding rounds or industry events that took place in China’s automotive market in January 2023. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.

CNMPA Approved World's First Inhaled COVID-19 Vaccine Mist

The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.

China Speed: Two COVID-19 Vaccines Recognized by WHO

As the second blow of the pandemic comes near the sight, China's newly-developed vaccines have been approved by the World Health Organization and available at an affordable price.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.